Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 11Terminated 6Recruiting 3Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Other solid neoplasm 1Head & Neck 1

Conditions

Solid Tumor, Adult 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Lymphoproliferative Disorders 1Epstein-Barr Virus Infections 1EBV Lymphomas 1Advanced Cancer 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Interventional × Valganciclovir × Clear all
NCT06391918 2026-03-13

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

GenVivo, Inc.

Phase 1 Terminated
37 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT05011058 2025-07-28

NAVAL-1

Viracta Therapeutics, Inc.

Phase 2 Terminated
102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

NCT06302140 2025-01-20

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Viracta Therapeutics, Inc.

Phase 1 Terminated
8 enrolled

Advanced Cancer

NCT00917826 2011-08-01

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

EBV Lymphomas

NCT00992732 2011-08-01

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡